All articles by Vijay Madhukar Singavarapu
Vijay Madhukar Singavarapu
M&As this week: Strides Pharma Science, Lambda Therapeutic Research, NextPharma
Strides Pharma Science’s step-down subsidiary Strides Pharma has made an arrangement to acquire Vensun Pharmaceuticals for $18m.
Deals this week: Medicines for Malaria Venture, Swedish Orphan Biovitrum, aTyr Pharma
Medicines for Malaria Venture (MMV) has entered a collaboration with Drugs for Neglected Disease initiative (DNDi) to create a pandemic response box.
Deals and M&As this week: Alnylam Pharmaceuticals, Novartis
Alnylam Pharmaceuticals has entered an agreement with Medison Pharma to commercialise its RNAi therapeutic Onpattro in Israel.
M&As this week: ProKidney, Quest Products, Gencore Pacific
ProKidney has acquired inRegen and its subsidiary Twin City Bio.
Deals this week: Sanofi, Knight Therapeutics, Ascletis Pharma
Sanofi has gained access to Biomunex Pharmaceuticals’ Plug-and-Play BiXAb platform through a licensing agreement.
M&As this week: Takeda, Eli Lilly, Claudio Bidco
Takeda Pharmaceutical has completed an acquisition of Shire for $62bn.
Deals this week: Sanofi, Biogen, Janssen Pharmaceuticals
Sanofi and Regeneron Pharmaceuticals have entered a revised agreement for the development of novel cancer treatments.
Deals and M&As this week: EQT, Sanofi, Bristol-Myers Squibb
EQT has agreed to increase its acquisition offer for Karo Pharma to Skr6.15bn ($694m) through the EQT VIII fund.
M&As this week: Astellas Pharma, Taisho Pharmaceuticals, AMAG Pharmaceuticals
Astellas Pharma has completed the acquisition of Potenza Therapeutics for $405m.
Deals this week: GlaxoSmithKline, Incyte, Novo Nordisk
GlaxoSmithKline (GSK) and Pfizer have agreed to combine their consumer healthcare businesses with combined annual sales of £9.8bn ($12.7bn) and establish a joint venture (JV).